Big pharma, Biotech

Proximagen biotech partnering with Lundbeck for protein kinase inhibitors

Posted on 02 October 2013

Tags: , , ,

Proximagen Limited has entered into a preclinical biotech partnering agreement with Lundbeck, a big pharma company, to further its research program related to protein kinase inhibitors.

This biotech partnering is part of Upsher-Smith's long-term strategy to advance its current product portfolio of branded drugs.

Specific terms related to the deal have not been disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on Lundbeck company profile, recent partnering, M&A and financing news and articles

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

Report: Partnering Deals and Alliances with Lundbeck

Report: Immunology Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply